Annual reportSep 2026
Sep 2026 · Shareholders meeting 4 Sep - 2nd AGM on 30 Sep 2026; annual report filed, with related-party, loan and remuneration approvals proposed.
Source: Nse
Vijaypd Ceutical Ltd. (VIJAYPD)
SME CapServices stocks · SME cap · NSE
Vijaypd Ceutical Ltd. operates in Pharma Services, within the Services sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹82.75
-1.25 · -1.49%
Market cap ₹176 Cr
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result01 Jun, 07:59 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage10/14 · 71%
Valuation2026-07-20 · Rf 6.8% · Services P/E 17.7 (n=143)
Technical timing lens
Trend score and candlestick chart
77Bullishfull bull SMA stack · SMA20 +24.4% / mo · MACD −
Stock trend: 77
Sector RS: —
Services FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
VIJAYPDD candles · FIT view-12.3%Latest close ₹82.75 on 2026-10-21
Bar
-2.6%
RSI
55
MACD hist
-0.38
52W pos
59%
2026-10-21O ₹85.00H ₹85.50L ₹82.00C ₹82.75Vol 8.2L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
VIJAYPDNifty 500
- VIJAYPD
- +19.9%
- Nifty 500
- -6.5%
- Vs Nifty 500
- +26.4 pp
Chart stats
21 Oct 2026- From 52W high
- -27.7%
- 52W range position
- 60%
- ATR (14)
- 6.4%
- Volume vs 20D
- 12.90x
- Avg traded value
- ₹0.9 Cr
- 20D price channel
- ₹63 - ₹100.1
₹114.5
₹35 - ₹114.5
₹5.3
Latest completed session
20-session average
115.8% annualized volatility
No exact NSE sector index is mapped for this company. Nifty 500 remains the broad-market comparison.
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED0
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model-337.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence60
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹47.6 Cr | NDF | -7.2% |
| EBITDA | ₹0.4 Cr | NDF | -92.0% |
| Operating margin | 0.7% | NDF | -776 bps |
| PAT | ₹2.6 Cr | NDF | +9.1% |
| PAT margin | 5.5% | NDF | +83 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 35.20
- P/B
- 3.36
- EV/EBITDA
- 35.50
- Market Cap
- 176.00Cr
Profitability
- ROE
- 9.54%
- ROCE
- —
- ROA
- 5.00%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- —
- EPS 5Y
- —
- Revenue 3Y
- —
- EPS 3Y
- —
Balance Sheet
- Debt/Equity
- 0.70
- Interest Coverage
- 2.50×
- Altman Z
- 4.06
- Book Value
- 26.90
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -9.00 Cr
- EPS TTM
- 2.56
Shareholding
- Promoter Hold
- 56.43%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 70%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 99.0-1.3% vs prev
Net Profit
₹ CrLatest: 5.1+7.4% vs prev
Return on Equity
%Latest: 9.6-33.7% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 55. Wait for confirmation.
- Price > SMA20 > SMA50 > SMA200 — full bullish stack.
- Recent golden cross (SMA50 crossed above SMA200).
- SMA20 rising (~19.6% over last month) — short-term momentum positive.
- RSI(14) at 55 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 28% off 52W high · 121% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
78
RS percentile
Stage 1 Base / Transition
1M return
+31.3%
3M return
+6.1%
6M return
+19.2%
1Y return
-
RS 1D
0
RS 20D
+57
Sector rank
#11
Industry rank
-
Stage evidence
- Price is within 7.8% of the 30-week proxy.
- The 30-week proxy changed +3.2% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price above
200-DMA
price above
Sector
improving
Industry
unranked
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
238 observations
21 Oct 2026Value 244.98-0.57%
RS vs Nifty 500245
Valuation & peers
U-Score 0 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 0 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth0/25
Quality0/20
Balance Sheet6/15
Cash Flow0/10
Piotroski
2/9 (+0)
Penalties
-8
Raw sum
-2
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
0/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 6/15 to the score.
- Valuation contributes 0/30 to the score.
- Growth contributes 0/25 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Fair-value margin of safety is negative at -337.4%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
35.2
PB
3.4
EV/EBITDA
35.5
ROE
9.5%
ROCE
—
FCF Yield
—
Debt/Equity
0.7
MoS
-337.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
0
Previous: 0
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-337.4%
Previous: -344.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
0
0
0
0
0
0
0
0
0
0
0
0
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹39.36
-110.2% MoS
Growth-justified P/E
7.4
Growth-justified Value
₹18.92
-337.4% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Services — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
RAPIDFLEET
SME
Rapid Fleet Management Services Ltd.
Logistics
match 84
58
12.2
16.1%
+53%
FAIR VALUE
BIRDYS
SME
Grill Splendour Services Ltd.
Hospitality
match 83
1
—
-27.4%
—
OVERVALUED
INNOVANA
Small
Innovana Thinklabs Limited
Pharmaceuticals
match 75
59
20.3
15.0%
+56%
FAIR VALUE
DRSDILIP
SME
DRS Dilip Roadlines Ltd.
Logistics
match -38
12
34.5
7.7%
-111%
OVERVALUED
LLOYDS
SME
Lloyds Luxuries Ltd.
Consumer Services
match -38
16
—
-4.3%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Vijaypd Ceutical Ltd. operates in Pharma Services, within the Services sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
60Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 28th percentile of the scored universe and 26th percentile within Services. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
28th percentile
overall median 67 · Services: 26th pctile, median 66 · SME: 32nd pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
80
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 56.4%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.00.
Trust risks
- ▸Operating cash flow is negative at ₹-9 Cr.
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Vijaypd Ceutical Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.